Denali Therapeutics (NASDAQ:DNLI) Price Target Raised to $38.00

Denali Therapeutics (NASDAQ:DNLI) had its price objective raised by BTIG Research from $36.00 to $38.00 in a research note published on Wednesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

DNLI has been the topic of a number of other reports. Morgan Stanley restated an “overweight” rating and set a $40.00 price objective on shares of Denali Therapeutics in a research note on Thursday, January 8th. Jefferies Financial Group reiterated a “buy” rating and issued a $40.00 target price on shares of Denali Therapeutics in a research report on Monday, March 2nd. Wolfe Research started coverage on shares of Denali Therapeutics in a research note on Monday, February 23rd. They set a “peer perform” rating on the stock. UBS Group initiated coverage on shares of Denali Therapeutics in a research report on Wednesday, January 7th. They set a “buy” rating on the stock. Finally, HC Wainwright upped their price target on shares of Denali Therapeutics from $32.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Denali Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $34.82.

Denali Therapeutics Stock Down 8.0%

DNLI opened at $18.16 on Wednesday. The stock’s 50 day moving average price is $20.43 and its 200 day moving average price is $17.83. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.16 and a quick ratio of 9.16. The stock has a market cap of $2.88 billion, a P/E ratio of -6.11 and a beta of 1.02. Denali Therapeutics has a 12 month low of $10.57 and a 12 month high of $23.77.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.02. During the same period last year, the business posted ($0.67) EPS. As a group, research analysts predict that Denali Therapeutics will post -2.71 earnings per share for the current year.

Insider Buying and Selling at Denali Therapeutics

In related news, CEO Ryan J. Watts sold 35,198 shares of the firm’s stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total transaction of $580,767.00. Following the completion of the transaction, the chief executive officer owned 296,833 shares of the company’s stock, valued at $4,897,744.50. This trade represents a 10.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Alexander O. Schuth sold 17,218 shares of Denali Therapeutics stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total value of $284,097.00. Following the transaction, the insider directly owned 282,828 shares in the company, valued at approximately $4,666,662. The trade was a 5.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 12.50% of the company’s stock.

Hedge Funds Weigh In On Denali Therapeutics

Hedge funds have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Denali Therapeutics by 4.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 88,507 shares of the company’s stock worth $1,210,000 after purchasing an additional 3,432 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in Denali Therapeutics by 58.1% during the first quarter. Goldman Sachs Group Inc. now owns 1,672,078 shares of the company’s stock worth $22,732,000 after buying an additional 614,555 shares in the last quarter. Empowered Funds LLC boosted its holdings in Denali Therapeutics by 11.0% during the first quarter. Empowered Funds LLC now owns 20,639 shares of the company’s stock worth $281,000 after buying an additional 2,052 shares in the last quarter. Woodline Partners LP grew its position in Denali Therapeutics by 13.5% in the first quarter. Woodline Partners LP now owns 113,517 shares of the company’s stock worth $1,543,000 after buying an additional 13,517 shares during the last quarter. Finally, PNC Financial Services Group Inc. grew its position in Denali Therapeutics by 120.1% in the second quarter. PNC Financial Services Group Inc. now owns 8,236 shares of the company’s stock worth $115,000 after buying an additional 4,494 shares during the last quarter. Institutional investors and hedge funds own 92.92% of the company’s stock.

Denali Therapeutics News Roundup

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: FDA approval of AVLAYAH — AVLAYAH received FDA approval as a brain‑targeting therapy for Hunter syndrome, giving Denali its first approved commercial asset and creating a clear commercialization pathway. Denali Wins FDA Nod for Hunter Syndrome Drug, Stock Up
• Positive Sentiment: Morgan Stanley raised its price target to $42 and kept an overweight rating — a large revision implying ~131% upside vs. the current price, signaling strong sell‑side confidence post‑approval. Benzinga
• Positive Sentiment: Goldman Sachs raised its target to $40 and reiterated a buy — another high target reflecting elevated expectations for AVLAYAH’s commercial prospects. Benzinga
• Positive Sentiment: Stifel, BTIG, HC Wainwright, Robert W. Baird also raised targets and/or ratings — most moved targets into the $32–$42 range and maintained buy/outperform views, adding upward pressure on the stock. (Sources include Benzinga and TickerReport.) Benzinga TickerReport
• Neutral Sentiment: Company discussion/transcript on commercial launch plans — management provided details on launch timing, supply and go‑to‑market strategy in a call/transcript, helping investors assess execution risk but not immediately changing fundamentals. Denali Discusses FDA Approval and Commercial Launch Plans for AVLAYAH (Transcript)
• Neutral Sentiment: Wider media coverage — outlets (MSN, Business Insider, Seeking Alpha) reported the FDA approval and will likely broaden investor and clinician awareness; coverage supports sentiment but execution and uptake remain the next items to watch. MSN Business Insider

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.